Outdoor activity decreases myopia risk

Article

Spending two to three hours a day outdoors can significantly lower a child's risk of developing myopia, according to study results published online ahead of print by the British Journal of Ophthalmology.

Spending two to three hours a day outdoors can significantly lower a child’s risk of developing myopia, according to study results published online ahead of print by the British Journal of Ophthalmology.

Terri Young, PhD of Duke University Medical Center, North Carolina, US and colleagues analyzed data on teenaged participants (n=1249) in the Singapore Cohort study Of Risk Factors for Myopia (SCORM) who had completed questionnaires quantifying outdoor activity.

A child’s chances of becoming nearsighted, if he or she has two nearsighted parents, are about six in 10 for children who spend 0 to 5 hours outside a week, but the risk drops to two in 10 when outdoor time exceeds 14 hours a week, the analysis found.

The researchers also noted that the critical factor for reducing development of myopia in children seems to be total time spent outdoors; both active and passive outdoor activities protected a child’s vision equally.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.